Increased risk of adverse cardiovascular events by strict glycemic control after percutaneous coronary intervention (HbA1c < 6.5% at 2 years) in type 2 diabetes mellitus combined with acute coronary syndrome: a 5-years follow-up study

References

• Blendea C, Chitu M, Orzan M, et al. The study of factors associated with severity of in-stent restenosis in patients treated with PCI for acute coronary syndromes. Acta Medica Marisiensis. 2016;62(1):64–67.
   Google Scholar
• Joseph J, Velasco A, Hage FG, et al. Guidelines in review: comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease. J Nucl Cardiol. 2017;25(2):1–7.
   PubMed Web of Science ®Google Scholar
• Nakano Y, Ishikawa T, Mutoh M. Long-term angiographic outcomes of sirolimus- and paclitaxel-eluting stent placement in diabetes, long lesions, and small vessels. Cardiovasc Interv and Ther. 2015;30(4):327–337.
   PubMed Web of Science ®Google Scholar
• Kato Y, Iwata A, Nakamura M, et al. In-stent restenosis due to stent recoil after third-generation drug-eluting stent implantation. J Clin Med Res. 2017;9(6):534–538.
   PubMedGoogle Scholar
• Takao T, Suka M, Yanagisawa H, et al. The impact of postprandial hyperglycemia at clinic visits on the incidence of cardiovascular events and all-cause mortality in patients with type 2 diabetes. J Diabetes Investig. 2017;8(4):600–608.
   PubMed Web of Science ®Google Scholar
• Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. Br Med J. 2011;343(jul26 1):d4169.
   PubMedGoogle Scholar
• Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–2473.
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139.
   PubMed Web of Science ®Google Scholar
• Parry HM, Deshmukh H, Levin D, V, et al. Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus. Circ Heart Fail. 2015;8(2):236–242.
   PubMed Web of Science ®Google Scholar
• Sharma PK, Agarwal S, Ellis SG, et al. Association of glycemic control with mortality in patients with diabetes mellitus undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2014;7(4):503–509.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Sara JD, Taher R, Kolluri N, et al. Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease. Cardiovasc Diabetol. 2019;18(1):22.
   PubMedGoogle Scholar
• Hwang JK, Lee SH, Song YB, et al. Glycemic control status after percutaneous coronary intervention and long-term clinical outcomes in patients with type 2 diabetes mellitus. Circ Cardiovasc Interv. 2017;10(8)e004157.
   PubMed Web of Science ®Google Scholar
• Grotti S, Liistro F, Angioli P, et al. Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: three-year results of the DEBATE-ISR study. J Endovasc Ther. 2016;23(1):52–57.
   PubMed Web of Science ®Google Scholar
• Iida O, Takahara M, Soga Y, et al. The characteristics of in-stent restenosis after drug-eluting stent implantation in femoropopliteal lesions and 1-year prognosis after repeat endovascular therapy for these lesions. JACC Cardiovasc Interv. 2016;9(8):828–834.
   PubMed Web of Science ®Google Scholar
• Marathe PH, Gao HX, Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. J Diabetes. 2017;9(4):320–324.
   PubMed Web of Science ®Google Scholar
• Introduction: Standards of Medical Care in Diabetes – 2018. Diabetes Care. 2018;41(Suppl 1):S1–S2.
   PubMed Web of Science ®Google Scholar
• Introduction: Standards of Medical Care in Diabetes – 2019. Diabetes Care. 42(Supplement 1):S1–S193.
   PubMedGoogle Scholar
• Tocci G, Barbato E, Coluccia R, et al. Blood pressure levels at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosis. AJHYPE. 2016;29(4):509–518.
   PubMed Web of Science ®Google Scholar
• Fereidoonnezhad B, Naghdabadi R, Sohrabpour S, et al. A mechanobiological model for damage-induced growth in arterial tissue with application to in-stent restenosis. J Mech Phys Solids. 2017;101:311–327.
   Web of Science ®Google Scholar
• Jiang H, Liu W, Liu Y, et al. High levels of HB-EGF and interleukin-18 are associated with a high risk of in-stent restenosis. Anatol J Cardiol. 2015;15(11):907–912.
   PubMed Web of Science ®Google Scholar
• Foo V, Quah J, Cheung G, et al. HbA1c, systolic blood pressure variability and diabetic retinopathy in Asian type 2 diabetics. J Diabetes. 2017;9(2):200–207.
   PubMed Web of Science ®Google Scholar
• Najafipour F, Mobasseri M, Yavari A, et al. Effect of regular exercise training on changes in HbA1c, BMI and VO2max among patients with type 2 diabetes mellitus: an 8-year trial. BMJ Open Diab Res Care. 2017;5(1):e000414.
   PubMed Web of Science ®Google Scholar
• Rajendran K, Manikandan S, Nair LD, et al. Serum chromium levels in type 2 diabetic patients and its association with glycaemic control. JCDR. 2015;9(11):OC05.
   PubMed Web of Science ®Google Scholar
• Mario I, Fabrizio D, Christian T, et al. Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2017;18(2):159–166.
   PubMed Web of Science ®Google Scholar
• Su J, Zhao L, Zhang X, et al. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients. Cardiovasc Diabetol. 2018;17(1):47–56.
   PubMedGoogle Scholar
• Celik IE, Yarlioglues M, Kurtul A, et al. Preprocedural albumin levels and risk of in-stent restenosis after coronary stenting with bare-metal stent. Angiology. 2016;67(5):478–483.
   PubMed Web of Science ®Google Scholar
• Pan W, Lu H, Lian B, et al. Prognostic value of HbA1c for in-hospital and short-term mortality in patients with acute coronary syndrome: a systematic review and meta-analysis. Cardiovasc Diabetol. 2019;18(1):169–180.
   PubMed Web of Science ®Google Scholar
• Mehanna E, Attizzani GF, Nakamura D, et al. Impact of neointimal calcifications on acute stent performance during the treatment of in-stent restenosis. Arq Bras Cardiol. 2016;106(5):419–421.
   PubMed Web of Science ®Google Scholar
• Group TAS. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care. 2016;39(5):701–708.
   PubMed Web of Science ®Google Scholar
• Hauk L. Preventing CVD in adults with type 2 diabetes mellitus: an update from the AHA and ADA. Am Fam Physician. 2016;93(3):232–233.
   PubMed Web of Science ®Google Scholar
• Funamizu T, Iwata H, Nishida Y, et al. Increased risk of cardiovascular mortality by strict glycemic control (pre-procedural HbA1c < 6.5%) in Japanese medically-treated diabetic patients following percutaneous coronary intervention: a 10-year follow-up study. Cardiovasc Diabetol. 2020;1(1):21–33.
   Google Scholar
• Ike A, Nishikawa H, Shirai K, et al. Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention–from the FU-registry. Circ J. 2011;75(4):791–799.
   PubMed Web of Science ®Google Scholar
• Sardar P, Udell JA, Chatterjee S, et al. Effect of intensive versus standard blood glucose control in patients with type 2 diabetes mellitus in different regions of the world: systematic review and meta-analysis of randomized controlled trials. JAHA. 2015;4(5):e001577.
   Google Scholar
• Azimova K, Juan ZS, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J. 2014;14(4):616–632.
   PubMedGoogle Scholar
• Lee W, Kim SH, Yoon CH, et al. Impact of long-term glycosylated hemoglobin in patients with acute myocardial infarction: a retrospective cohort study. Sci Rep. 2020;10(1):6726–6735.
   PubMed Web of Science ®Google Scholar
• Looser PM, Kim LK, Feldman DN. In-stent restenosis: pathophysiology and treatment. Curr Treat Options Cardiovasc Med. 2016;18(2):10–12.
   PubMedGoogle Scholar
• Forde H, Harper E, Davenport C, et al. The beneficial pleiotropic effects of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) within the vasculature: a review of the evidence. Atherosclerosis. 2016;247:87–96.
   PubMed Web of Science ®Google Scholar
• Batnyam U, Ko NK, Javaid A. Hypoglycemia-associated in-stent thrombosis: are we doing too much?. Cureus. 2017;9(9):e1712.
   PubMed Web of Science ®Google Scholar
• Lei H, Li J, Zhao Z, et al. Inhibition of ectodermal-neural cortex 1 protects neural cells from apoptosis induced by hypoxia and hypoglycemia. J Mol Neurosci. 2016;59(1):126–129.
   PubMed Web of Science ®Google Scholar
• Kim HM, Lim JS, Lee BW, et al. Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus. Endocrinol Metab. 2015;30(1):84–91.
   Google Scholar
• Hamada S, Gulliford MC. Mortality in individuals aged 80 and older with type 2 diabetes mellitus in relation to glycosylated hemoglobin, blood pressure, and total cholesterol. J Am Geriatr Soc. 2016;64(7):1425–1431.
   PubMed Web of Science ®Google Scholar
• Neupane S, Dubey RK, Gautam N, et al. Association between serum uric acid, urinary albumin excretion, and glycated hemoglobin in type 2 diabetic patient. Niger Med J. 2016;57(2):119–123.
   PubMedGoogle Scholar
• Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Dia Care. 2019;42(3):416–426.
   PubMed Web of Science ®Google Scholar